The Latest Breaking News from Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

A Relative Strength Rating upgrade for Ginkgo Bioworks Holdings shows improving technical performance.

Ginkgo Bioworks Holdings's (NYSE:DNA) short percent of float has risen 9.65% since its last report. The company recently reported that it has 81.30 million shares sold short, which is 10.34% of all regular shares that are available for trading.

Gainers Ginkgo Bioworks Holdings (NYSE:DNA) shares rose 9.9% to $4.11 during Tuesday's pre-market session. The market value of their outstanding shares is at $6.8 billion. The company's, Q4 earnings came out yesterday.

Ginkgo Bioworks (DNA) went public last September through an SPAC deal with Soaring Eagle Acquisition Corporation, a blank-check company led by former MGM CEO Harry Sloan. However, the stock has nosedived in price since its market debut. In addition, given an ongoing investigation into the company and its weak financials,…